

**PRESSURE BIOSCIENCES INC.**

14 Norfolk Avenue  
South Easton, MA 02375  
(T) 508-230-1828  
(F) 508-230-1829  
[info@pressurebiosciences.com](mailto:info@pressurebiosciences.com)

Mr. Richard T. Schumacher, CEO, President  
Dr. Edmund Y. Ting, SVP of Engineering  
Dr. Nathan P. Lawrence, Vice President of M&S  
Dr. Alexander V. Lazarev, Vice President of R&D  
Mr. Joseph L. Damasio Jr, VP of Finance and CFO

---

**STOCK OVERVIEW**

Symbol:	PBIO	Recent Bid:	\$3.50 (as of 12/29/17)
Exchange:	OTCQB	52-Week Range:	\$0.70 - \$17.40
Shares OS <sup>1</sup> :	2.7M (Fully Diluted)	Market Capitalization <sup>2</sup> :	\$10.2M
Float:	~1.0M	Fiscal Year End:	December 31
Revenue (FY2016):	\$2.0M	Transfer Agent:	Computershare

---

**COMPANY OVERVIEW**

**Pressure BioSciences, Inc. ("PBI")** is a life sciences tools company focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on our game-changing Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (up to 100,000 psi) to safely, conveniently and reproducibly control the actions of molecules (i.e., inactivate, break (lyse), liberate, extract, and/or prepare for downstream analysis) from biological samples, such as cells and tissues from human, animal, plant, and microbial sources. We currently focus the majority of our efforts on the development and sale of PCT systems (instruments and consumables) to address the challenging problems inherent in biological sample preparation, a crucial laboratory step performed by thousands of scientists worldwide working in biological life sciences research.

Sample preparation is a term that refers to a wide range of activities that precede most forms of scientific analysis. Sample preparation is often complex, time-consuming, and one of the most error-prone (but crucial) steps of scientific research. It is a widely-used laboratory undertaking, the requirements of which drive a large and growing market, estimated currently at approximately \$6 billion worldwide. PBI's PCT systems can be used to exquisitely control the sample preparation process. PCT uses internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels, at specific temperatures and time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as DNA, RNA, proteins, lipids, metabolites, and other small molecules. Our product line includes five different models of pressure-generating instruments and over a dozen different consumables. Together the instruments and consumables make up our PCT Sample Preparation System, or PCT Platform.

Our website contains over 100 publications, many from world-renowned scientists, addressing key attributes and advantages of PCT. These advantages include: (a) extraction and recovery of more integral, membrane-bound proteins versus competitive methods (approximately 80% of all new biological drugs in development are directed against such proteins); (b) significantly enhanced proteolysis (digestion of proteins); (c) differential lysis (breakage) of targeted cell types in a mixed sample base (i.e., female skin cells vs. male sperm heads in a rape kit swab sample); (d) ability to fully inactivate dangerous pathogens, such as anthrax; (e) increased detection of DNA and proteins in forensic, infectious disease, cancer, cardiac, neonatal, and other sample types; and (f) the ability to exquisitely control and standardize the sample preparation process.

Through November 14, 2017, PBI has sold or leased approximately 300 PCT Sample Preparation Systems to approximately 175 leading academic, government, biotech, and pharmaceutical companies worldwide. Current customers use the PCT Platform for a wide assortment of important applications, including the preparation of samples for biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

- 
1. Shares Outstanding (as of December 31, 2017) – includes approximately 1.311M common shares, 0.5 common share equivalents from Preferred Stock Series D, G, H, J, and K on an as-converted basis, and 1.1M 2015/16 PIPE Debentures.
  2. Market Capitalization is calculated using Common and Common Equivalent Shares OS on a Fully Diluted basis. The Company has no Warrants or Stock Options that are "in the money".

## INVESTMENT HIGHLIGHTS

- Seasoned Management Team & Board of Directors
- Novel, Enabling, Patent Protected, Proprietary Platform (PCT)
- Proven Core Technology with Multiple Applications (over 270 PCT systems placed)
- Razor/Razorblade Business Model
- Sales into the Research Market (fast market penetration with minimal approvals required)
- Increasing Number of 3rd Party Publications from Marquee Laboratories
- PCT Breaks Through Bottlenecks and Barriers to Enable and Accelerate Scientific Discovery
- PCT Exquisitely Controls Test Variables, Providing Methods Standardization/Reproducibility
- Significant Market Opportunity (~\$6 Billion from ~500K scientists in 80K labs worldwide)

---

## RECENT & KEY ANNOUNCEMENTS

- **December 20, 2017:** the Company announced a significant software upgrade for its flagship Barocycler 2320EXTREME instrument.
- **December 18:** the Company announced it would host an investor call to discuss the BaroFold asset purchase, the recently patented Ultra Shear Technology (“UST”) platform, enhancements to its core pressure-based instrument and consumables business, and would offer a brief outlook for FY2018.
- **December 13:** the Company announced the acquisition of all the assets of BaroFold Corp, and its immediate entry into the Biologics Contract Research Services Sector.
- **November 14:** the Company reported third quarter 2017 financial results, including record total revenue led by increases in products and services (+21%), consumables (+158%), and grant (+23%) sales.
- **November 1:** the Company announced the initiation of an aggressive marketing and sales strategy that PBI expects will drive significant expansion in China.
- **October 18:** the Company announced a strategic collaboration with Phasex Corporation, to combine PBI’s Ultra Shear Technology with Phasex’s Supercritical Fluid Processing Method to enable the development of stable, water-soluble nanoemulsions, including CBD-enriched plant oil.
- **October 10:** the Company announced multiple presentations at scientific meetings in Germany, Poland, and Ireland highlighting the features & benefits of the Company’s next-generation Barocycler 2320EXT instrument.
- **October 2:** the Company announced it was issued two patents on its widely-applicable, high pressure-based Ultra Shear Technology. PBI believes that UST can be used to create or improve a broad range of medical, consumer, and industrial products through the preparation of high quality nanoemulsions and “clean label” food.
- **September 18:** the Company announced that the Barocycler 2320EXTREME was named a Finalist in the prestigious 2017 R&D 100 Awards. Considered among the most prestigious recognitions of invention and innovation worldwide, the R&D 100 awards identify the top 100 revolutionary technologies of the past year.
- **August 16:** the Company announced Q2 and YTD 2017 financial results, which included year-over-year quarterly increases in total revenue and product and services revenue.
- **June 6:** the Company announced that the Barocycler 2320EXTREME was to be featured in multiple presentations all week at the major ASMS scientific conference, and that compelling advantages of the Company’s PCT platform were highlighted in two different mass spectrometry user meetings on Day One.
- **June 5:** the Company announced that Dr. Ruedi Aebersold received the prestigious Karger Medal for significant contributions to the development of new bioanalytical methods, and that he discussed PBI’s patented PCT platform for sample preparation – a critical step in scientific analysis – during his Medal Lectures.
- **June 2:** the Company announced a one-for-thirty reverse stock split effective Monday, June 5.
- **May 16:** the Company announced Q1 2017 financial results: (a) product and services revenue increased 16% over the same quarter of 2016, led by a 43% increase in consumable sales and a 19% increase in instrument sales; (b) total revenue increased 8% over the same period in 2016; and (c) operating loss decreased 4% during the first quarter 2017 compared to the first quarter 2016.
- **April 17:** the Company announced the hire of Joseph L. Damasio, Jr as its VP of Finance and CFO. This move will allow the Company’s CEO (Mr. Richard T. Schumacher), who had been filling the role of CFO for over two years, to focus much more time on the Company’s on-going operations, growth plans and business strategy.
- **March 1:** the Company’s Barocycler, the 2320EXTREME, received the 2017 N. American Excellence Award for “Best New Instrument for Sample Preparation” by Corporate America News, a leading business publication.
- **February 2, 2017:** the Company announced that the Barocycler 2320EXT had been approved to be CE Marked.
- **October 26,** PBI reported that its PCT platform was featured at the official launch of a major cancer research center (ProCan – Sydney, AU); ProCan is an official collaborator to the NCI in the NIH’s “Cancer Moonshot”.
- **July 13:** the new, next-generation Barocycler 2320EXT is unveiled at the June 2016 ASMS Annual Meeting.
- **January 12, 2016:** SCIEX, a global leader in life science analytical technologies, and a wholly-owned subsidiary of Danaher Corporation (NYSE: DHR), announces an exclusive co-marketing agreement with PBI to improve protein quantitation in complex samples

---

## BOARD OF DIRECTORS

- Mr. Jeffrey N. Peterson, Chairman
- Mr. Kevin A. Pollack, Esq.
- Mr. Vito Mangiardi
- Dr. Mickey Urdea
- Mr. Richard T. Schumacher

12/29/2017